Zepbound (tirzepatide) is a once-weekly injectable prescription medication manufactured by Eli Lilly and Company. It is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition

Sources

FDA label: Zepbound (tirzepatide) injection, Eli Lilly and Company, NDA 217806, current labeling as of 2025
SURMOUNT-1 trial: Jastreboff AM et al., NEJM 2022;387:205-216
SURMOUNT-2 trial: Garvey WT et al., Lancet 2023;402:613-626
SURMOUNT-OSA trial: Malhotra A et al., NEJM 2024;391:1916-1927
FDA approval announcement: Zepbound for obstructive sleep apnea, December 20 2024
Eli Lilly Zepbound Savings Card program terms, updated January 2026
CMS Medicare Part D coverage data, 2026 plan year

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.